Novaliq’s Bernhard Günther Reveals Company’s Fateful Start, Promising Future for Dry Eye Treatments

OIS Podcast | Ophthalmology's leading Podcast

English - April 02, 2019 04:00 - 30 minutes - 14.1 MB - ★★★★★ - 30 ratings
Investing Business Health & Fitness ophthalmology investment venture capital entrepreneurs oftalmólogo ophthalmic key opinion leader seco ascrs aao Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: What Impact Will Gene Therapy Deals Have on Patients? Start-Ups? Jay Duker, MD, Can Speak for Both.

Next Episode: Oyster Point Pharma CEO Jeffrey Nau Highlights Details of the Company’s Recent B Round, Ponders IPO

After entering the ophthalmology industry “by accident,” Bernhard Günther founded Novaliq in 2004 to pursue therapeutic applications for CyclASol, a novel solution used in drug delivery. While Novaliq pursued other therapeutic applications initially, fate once again brought Günther back into ophthalmology. Today, the company is positioned to deliver two new treatments for dry eye disease. In this podcast we’ll cover the company’s origins, its unusual investor, and its move to the US.